Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010.
Article
PubMed
Google Scholar
Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005, 97 (19): 1407-1427. 10.1093/jnci/dji289.
Article
PubMed
Google Scholar
Sawhney R, Sehl M, Naeim A: Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2005, 11 (6): 449-460. 10.1097/00130404-200511000-00004.
Article
PubMed
Google Scholar
Sehl M, Sawhney R, Naeim A: Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 2005, 11 (6): 461-473. 10.1097/00130404-200511000-00005.
Article
PubMed
Google Scholar
Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP: Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011, 29 (25): 3457-3465. 10.1200/JCO.2011.34.7625.
Article
CAS
PubMed
PubMed Central
Google Scholar
Soubeyran P, Fonck M, Blanc-Bisson C, Blanc JF, Ceccaldi J, Mertens C, Imbert Y, Cany L, Vogt L, Dauba J, Andriamampionona F, Houédé N, Floquet A, Chomy F, Brouste V, Ravaud A, Bellera C, Rainfray M: Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012, 30 (15): 1829-1834. 10.1200/JCO.2011.35.7442.
Article
PubMed
Google Scholar
Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ: Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993, 342 (8878): 1032-1036. 10.1016/0140-6736(93)92884-V.
Article
CAS
PubMed
Google Scholar
Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006, 24 (25): 4085-4091. 10.1200/JCO.2006.06.9039.
Article
CAS
PubMed
Google Scholar
Mattioli R, Massacesi C, Recchia F, Marcucci F, Cappelletti C, Imperatori L, Pilone A, Rocchi M, Cesta A, Laici G, Bonsignori M, Lippe P: High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol. 2005, 16 (7): 1147-1151. 10.1093/annonc/mdi222.
Article
CAS
PubMed
Google Scholar
Sastre J, Aranda E, Massuti B, Tabernero J, Chaves M, Abad A, Carrato A, Reina JJ, Queralt B, Gomez-Espana A, Gonzalez-Flores E, Rivera F, Losa F, Garcia T, Sanchez-Rovira P, Maestu I, Diaz-Rubio E: Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol. 2009, 70 (2): 134-144. 10.1016/j.critrevonc.2008.11.002.
Article
PubMed
Google Scholar
Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE: Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011, 377 (9779): 1749-1759. 10.1016/S0140-6736(11)60399-1.
Article
CAS
PubMed
PubMed Central
Google Scholar
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D, First BEAT investigators: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009, 20 (11): 1842-1847. 10.1093/annonc/mdp233.
Article
CAS
PubMed
Google Scholar
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, et al: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012, 23 (10): 2479-2516. 10.1093/annonc/mds236.
Article
CAS
PubMed
Google Scholar
Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, Fu AZ, Sansbury LB, Potosky AL: Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol. 2013, 24 (6): 1574-1579. 10.1093/annonc/mdt019.
Article
PubMed
PubMed Central
Google Scholar
Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP, AVEX study investigators: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013, 14 (11): 1077-1085. 10.1016/S1470-2045(13)70154-2.
Article
CAS
PubMed
Google Scholar
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92 (3): 205-216. 10.1093/jnci/92.3.205.
Article
CAS
PubMed
Google Scholar
Basso U, Monfardini S: Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care (Engl). 2004, 13 (5): 424-433. 10.1111/j.1365-2354.2004.00551.x.
Article
CAS
Google Scholar
Kakolyris S, Souglakos J, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulias V, Hellenic Oncology Research Group: Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. Oncology. 2008, 74 (1–2): 31-36.
Article
CAS
PubMed
Google Scholar
Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, Cretin J, Locher C, Bouche O, Breysacher G, Charneau J, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Mitry E: Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013, 31 (11): 1464-1470. 10.1200/JCO.2012.42.9894.
Article
CAS
PubMed
Google Scholar
Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A: Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010, 78 (5–6): 329-339.
Article
CAS
PubMed
Google Scholar
Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O: Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009, 27 (2): 199-205. 10.1200/JCO.2008.17.7931.
Article
CAS
PubMed
Google Scholar
Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC: Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol. 2012, 23 (6): 1531-1536. 10.1093/annonc/mdr488.
Article
CAS
PubMed
Google Scholar
Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M: Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol. 2012, 51 (7): 831-839. 10.3109/0284186X.2012.699193.
Article
CAS
PubMed
Google Scholar